Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Return on Capital Employed for 5 consecutive years, with 0.66% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 1118.0% to 0.66% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.66%, a 1118.0% increase, with the full-year FY2024 number at 0.54%, up 69.0% from a year prior.
  • Return on Capital Employed was 0.66% for Q3 2025 at Inhibikase Therapeutics, down from 0.53% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.24% in Q3 2021 to a low of 11.84% in Q3 2024.
  • A 5-year average of 1.57% and a median of 0.67% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -1069bps in 2024, then soared 1118bps in 2025.
  • Inhibikase Therapeutics' Return on Capital Employed stood at 0.37% in 2021, then tumbled by -114bps to 0.79% in 2022, then plummeted by -100bps to 1.58% in 2023, then surged by 62bps to 0.6% in 2024, then dropped by -10bps to 0.66% in 2025.
  • Per Business Quant, the three most recent readings for IKT's Return on Capital Employed are 0.66% (Q3 2025), 0.53% (Q2 2025), and 0.44% (Q1 2025).